Supriya Bio-Tech Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 25-12-2024
- Paid Up Capital ₹ 2.44 M
as on 25-12-2024
- Company Age 23 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 0.60 M
as on 25-12-2024
- Revenue %
(FY 2020)
- Profit 29.36%
(FY 2020)
- Ebitda 25.47%
(FY 2020)
- Net Worth -0.32%
(FY 2020)
- Total Assets 0.04%
(FY 2020)
About Supriya Bio-Tech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 2.44 M.
The company has closed loans amounting to ₹0.60 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Priyanka Raizada and Puneet Raizada serve as directors at the Company.
- CIN/LLPIN
U24230MH2001PTC133492
- Company No.
133492
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Sep 2001
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Supriya Bio-Tech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Priyanka Raizada  | Director | 28-Sep-2001 | Current |
| Puneet Raizada | Director | 15-Dec-2007 | Current |
Financial Performance of Supriya Bio-Tech.
Supriya Bio-Tech Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 29.36% increase in profit. The company's net worth dipped by a decrease of 0.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Supriya Bio-Tech?
In 2018, Supriya Bio-Tech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Puneet Laboratories Private LimitedActive 38 years 2 monthsPriyanka Raizada and Puneet Raizada are mutual person
Himar Specialty Chemicals Private LimitedActive 27 years 2 monthsPriyanka Raizada and Puneet Raizada are mutual person
- Innomac Healthcare Equipments Private LimitedActive 21 years 4 months
Priyanka Raizada and Puneet Raizada are mutual person
- Optimum Thrive Platforms Private LimitedActive 1 year 8 months
Priyanka Raizada and Puneet Raizada are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Corporation Bank Creation Date: 30 Mar 2003 | ₹0.60 M | Satisfied |
How Many Employees Work at Supriya Bio-Tech?
Unlock and access historical data on people associated with Supriya Bio-Tech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Supriya Bio-Tech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Supriya Bio-Tech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
